Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.98 USD
-0.02 (-1.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.97 -0.01 (-0.51%) 6:38 PM ET
1-Strong Buy of 5 1
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ENTX 1.98 -0.02(-1.00%)
Will ENTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENTX
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
Other News for ENTX
Biotech Alert: Searches spiking for these stocks today
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Biotech Alert: Searches spiking for these stocks today
Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research